The breast cancer immune microenvironment is modified by neoadjuvant chemotherapy
Abstract Neoadjuvant chemotherapy (NAT) in breast cancer (BC) has been used to reduce tumor burden prior to surgery. However, the impact on prognosis depends on the establishment of Pathological Complete Response (pCR), which is influenced by tumor-infiltrating lymphocyte levels and the activation o...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-05-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-12108-5 |